Inspiring Science, Inspiring Teamwork, Inspiring Entrepreneurship @argenx . See below for the full interview with our CEO Tim Vanhauwermeiren.
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
In the latest episode of Exceptional Leaders / Exceptional Ideas, our CEO Tim Van Hauwermeiren discusses his entrepreneurial journey, navigating the launch of argenx, and our approach to developing innovative treatments for autoimmune conditions. Watch the full episode below.
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
R&D, Drug Development & Medical Affairs, Market Access Global Clinical Studies and Product Lifecycle Management, RA, Board of Directors, International Speaker, Development Programs, Strategic Leadership.
Not easy to start a new company
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
Today's the day. Check out my presentation at Fierce Biotech JPM week on success factors for the biotech company journey from discovery to commercialization. You can register here. https://lnkd.in/eQTYR4nE
Our CEO, Dr. J. Jean Cui, connected with BiotechTV’s Brad Loncar following our completion of a $100 million financing to gain insight into Dr. Cui’s perspective on #precisionmedicines and how we are working to solve unmet medical needs by re-envisioning #cancer drug development. Watch the full video here: https://bit.ly/3Isffxy
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: BlossomHill Therapeutics, Inc. raises a $100M series B to work on precision medicine small molecules. Scientific founder, president & CEO J. Jean Cui describes the company's approach. Full video: https://lnkd.in/gfYWVuUT BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
AAX Biotech Secures Funding to Drive Technology Development and Expansion 🚀 We are excited to announce that AAX Biotech AB has successfully raised 7 MSEK in a funding round backed by both new and existing investors. The capital will be used to support our ongoing growth and innovation efforts, strengthening our internal capabilities and expanding our project portfolio. The funding round included a rights issue offered to current shareholders, alongside a directed share issue aimed at new investors such as Life Science Invest (LSI Epsilon). Several existing shareholders, including Karolinska Institutet Holding, Northislet, Hjalmar Didrikson through HJKK Didrikson AB and Phase2Phase Biopharma Ventures, additionally chose to increase their stake in AAX Biotech. With these resources, we are positioned to deliver innovative solutions that address some of the most critical medical challenges. Full story: https://lnkd.in/dcSBZ5Mm #AAX #Biotech #AntibodyTherapeutics #NextGenTherapeutics #DrugDevelopment
Afinum acquires a majority stake in evitria Abolon was mandated by Afinum Management GmbH, the DACH-based private equity firm, on its acquisition of a majority stake in Swiss biotech company evitria AG, which provides custom antibodies for research purposes. evitria has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies to date. The company’s success is based on a unique, highly standardized and automatized production process that minimizes throughput times and guarantees high concentrations and quality levels, thereby perfectly addressing its customers’ need for specific, tailor-made antibodies. Its business model has allowed evitria to build a reputation of a superior biotech specialist and trustworthy outsourcing partner. The transaction has been closed in December 2018. The enterprise value was not made publicly available. Abolon Group was exclusively mandated by Afinum.
Thoughts on this? >> VC firm emerges to boost Austrian biotech scene that’s ‘ready to break out’ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #biotech #healthcare
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> VC firm emerges to boost Austrian biotech scene that’s ‘ready to break out’ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech
Don’t miss out on our dedicated track for Strategy and Dealmaking at the Fierce Biotech Summit on Sept 30th – Oct 1st. ➡️Click here to learn more https://ow.ly/BWJR50SzHck Explore the dynamics of partnerships, collaborations, and investments in biotech. Examine the changing landscape of deal structures, innovative licensing models, and successful case studies of strategic alliances. Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FiercePharma #BiotechPR #BiotechEvents
